Disorders of glucose metabolism in the context of human immunodeficiency virus infection

Journal of the American Academy of Nurse Practitioners

Volumn 18, Issue 3, 2006, Pages 92-103

  Larson, Ruth ^b   Capili, Bernadette ^c   Eckert Norton, Margaret ^d   Colagreco, Joseph P ^e   Anastasi, Joyce K ^a,c  

^a Department of Nursing ^*

^b Internal Medicine   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e Harlem United Community AIDS Center   (United States)

Author keywords

Glucose metabolism; HIV; Insulin resistance; Metabolic syndrome

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; PROTEINASE INHIBITOR;

ALGORITHM; CARDIOVASCULAR DISEASE; COMORBIDITY; DECISION TREE; DIABETES MELLITUS; FEEDING BEHAVIOR; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIFESTYLE; METABOLISM; NURSING ASSESSMENT; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; RISK REDUCTION; SUBSTANCE ABUSE; VIROLOGY;

ALGORITHMS; ANTI-HIV AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; COMORBIDITY; DECISION TREES; DIABETES MELLITUS; FOOD HABITS; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; NURSING ASSESSMENT; PRACTICE GUIDELINES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 33646851614     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2006.00109.x     Document Type: Article

References (68)

1. Addy, C. L., Gavrila, A., Tsiodra, S., Brodovicz, K., Karchmer, A. W. Mantzoros, C. S 2003). Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. Journal of Clinical Endocrinology Metabolism, 88, 627 636.
2. Adult AIDS Clinical Trials Group 2002a). AACTG metabolic guides: Disorders of glucose metabolism: Insulin resistance and diabetes mellitus. Retrieved March 16, 2005, from http://aactg.s-3.com/metabolic/diabetes.pdf
3. Adult AIDS Clinical Trials Group 2002b). AACTG metabolic guides: Lipid disturbances. Retrieved March 16, 2005, from http://aactg.s-3.com/metabolic/ lipid.pdf
4. American Association of Clinical Endocrinologists (AACE) & American College of Endocrinology (ACE) 2002). The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management - 2002 update. Endocrine Practice, 8 (Suppl. 1 40 82.
5. American Diabetes Association 2005). Diagnosis and classification of diabetes mellitus. Diabetes Care, 28 (Suppl. 1 S37 S42.
6. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, &North American Association for the Study of Obesity 2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596 601.
7. Andersen, O., Haugaard, S. B., Andersen, U. B., Friis-Moller, N., Storgaard, H., Volund, A, et al. 2003). Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in β-cell function. Metabolism, 52, 1343 1353.
8. Barbaro, G 2003). HIV infection, highly active antiretroviral therapy and the cardiovascular system. Cardiovascular Research, 60, 87 95.
9. Barnett, P. S. Braunstein, G. D 2004). Diabetes mellitus. In C. C. J. Carpenter, R. C. Griggs J. Loscalzo (Eds Cecil essentials of medicine (6th ed Philadelphia : W.B. Saunders.
10. Behrens, G., Dejam, A., Schmidt, H., Balks, H., Brabant, G., Korner, T, et al 1999). Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS, 13, F63 F70.
11. Ben-Romano, R., Rudich, A., Torok, D., Vanounou, S., Riesenberg, K., Schlaeffer, F, et al 2003). Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS, 17, 23 32.
12. Chung, R. T., Anderson, J., Volberding, P., Robbins, G. K., Liu, T., Sherman, K. E, et al 2004). Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine, 351, 451 459.
13. Chung, R. T., Casson, D. R., Murray, G., Song, S., Grinspoon, S. Hadigan, C 2003). Alanine aminotransferase levels predict insulin resistance in HIV lipodystrophy. Journal of Acquired Immune Deficiency Syndrome, 34, 534 536.
14. Cohen, D 2004). Atypical antipsychotics and new onset diabetes mellitus. Pharmacopsychiatry, 37, 1 11.
15. Cooper, O. B., Brown, T. T. Dobs, A. S 2003). Opiate drug use: A potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clinical Infectious Diseases, 37 (Suppl. 2 S132 S136.
16. Dandona, P., Aljada, A. Bandyopadhyay, A 2004). Inflammation: The link between insulin resistance, obesity and diabetes. Trends in Immunology, 25, 4 7.
17. Dolder, C. R., Patterson, T. L. Jeste, D. V 2004). HIV, psychosis, and aging: Past, present, and future. AIDS, 18 (Suppl. 1 35 42.
18. Dube, M. P 2000). Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clinical Infectious Diseases, 31, 1467 1475.
19. Duong, M., Petit, J. M., Piroth, L., Grappin, M., Buisson, M., Chavanet, P, et al 2001). Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome, 27, 245 250.
20. Fantoni, M., Del Borgo, C. Autore, C 2003). Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS, 17 (Suppl. 1 S162 S169.
21. Flier, J. S. Mantzoros, C 2005). Insulin resistance: Definition and clinical spectrum. Uptodate. Retrieved from http://www.uptodate.com
22. Funnell, M. M. Durger, D. F 2004). Type 2 diabetes: Treat to target. The Nurse Practitioner, 29, 11 25.
23. Garg, A 2004). Acquired and inherited lipodystrophies. New England Journal of Medicine, 350, 1220 1234.
24. Gelato, M. C 2003). Insulin and carbohydrate dysregulation. Clinical Infectious Diseases, 36 (Suppl. 2 S91 S95.
25. Grinspoon, S 2003). Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clinical Infectious Diseases, 37 (Suppl. 2 S85 S90.
26. Grundy, S. C., Cleeman, J. I., Merz, N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B, et al 2004). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110, 227 239.
27. Grunfeld, C. Tien, P 2003). Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clinical Infectious Diseases, 37 (Suppl. 2 S43 S46.
28. Hadigan, C., Corcoran, C., Basgoz, N., Davis, B., Sax, P. Grinspoon, S 2000). Metformin in the treatment of HIV lipodystrophy syndrome. Journal of the American Medical Association, 284, 472 477.
29. Hadigan, C., Jeste, S., Anderson, E. J., Tsay, R., Cyr, H. Grinspoon, S 2001). Modifiable dietary habits and their relation to abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clinical Infectious Diseases, 33, 710 717.
30. Hadigan, C., Rabe, J., Meininger, G., Aliabadi, N., Breu, J. Grinspoon, S 2003). Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. American Journal of Clinical Nutrition, 77, 490 494.
31. Herbst, K. L. Hirsch, I. B 2002). Insulin strategies for primary care providers. Clinical Diabetes, 20, 11 17.
32. Holstein, A., Plaschke, S. Egberts, EH. (2001). Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection. Experimental Clinical Endocrinology Diabetes, 109, 389 392.
33. Hui, J. M., Sud, A., Farrell, G. C., Bandara, P., Byth, K., Kench, J. G, et al 2004). Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology, 125 (6 1695 1704.
34. Jones, S. P., Doran, D. A., Leatt, P. B., Maher, B. Pirmohamed, M 2001). Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS, 15, 2049 2051.
35. Khalsa, J. H., Genser, S., Coates, P. Francis, H 2003). Interventions for metabolic and endocrine complications of human immunodeficiency virus/acquired immune deficiency syndrome and illicit drug use. Clinical Infectious Diseases, 37 (Suppl. 2 S37 S42.
36. Kinlaw, W. B. Marsh, B 2004). Adiponectin and HIV-lipodystrophy: Taking HAART. Endocrinology, 145, 484 486.
37. Kino, T., Mirani, M., Alesci, S. Chrousos, G. P 2003). AIDS-related lipodystrophy/insulin resistance syndrome. Hormone & Metabolism Research, 35, 129 136.
38. Koster, J. C., Remedi, M. S., Qui, H., Nichols, C. G. Hruz, P. W 2003). HIV protease inhibitors acutely impair glucose-stimulated insulin response. Diabetes, 52, 1695 1700.
39. Kotler, D. P., Ionescu, G., Johnson, J. A., Inada, Y., He, Q., Engelson, E. S, et al 2003). Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clinical Infectious Diseases, 37 (Suppl. 2 S47 S51.
40. Koutkia, P. Grinspoon, S 2004). HIV-associated lipodystrophy: Pathogenesis, prognosis, treatment and controversies. Annual Review of Medicine, 55, 303 317.
41. Lebovitz, H. E 2001). Oral therapies for diabetic hyperglycemia. Endocrinology Metabolism Clinics of North America, 30, 909 933.
42. Lebovitz, H. E 2004). Diabetes pathophysiology. Lecture at SUNY Downstate Medical Center, February 26, 2004.
43. Lebovitz, H. E. Banerji, M. A 2001). Insulin resistance and its treatment by thiazolidinediones. Recent Progress in Hormone Research, 56, 265 294.
44. Lebovitz, H. E. Banerji, M. A 2004). Treatment of insulin resistance in diabetes mellitus. European Journal of Pharmacology, 490, 135 146.
45. Lecube, A., Hernandez, C., Genesca, J., Esteban, J. I., Jardi, R. Simo, R 2004). High prevalence of glucose abnormalities in patients with hepatitis C virus infection. Diabetes Care, 27, 1171 1175.
46. Leow, M. K. S., Addy, C. L. Mantzoros, C. S 2003). Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: Clinical presentation, pathophysiology, and therapeutic strategies. Journal of Clinical Endocrinology Metabolism, 88, 1961 1976.
47. Limone, P., Biglino, A., Valle, M., Degioanni, M., Servato, M. P., Berardi, C, et al 2003). Insulin resistance in HIV-infected patients: Relationship with pro-inflammatory cytokines released by peripheral leukocytes. Journal of Infection, 47, 52 58.
48. Luscher, T. F., Creager, M. A., Beckman, J. A. Cosentino, F 2003). Diabetes and vascular disease - Pathophysiology, clinical consequences, and medical therapy: Part II. Circulation, 108, 1655 1661.
49. Meigs, J. B., Williams, K., Sullivan, L. M., Hunt, K. J., Haffner, S. M., Stern, M. P, et al 2004). Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care, 27, 1417 1426.
50. Meininger, G., Hadigan, C., Rietschel, P. Grinspoon, S 2002). Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. American Journal of Clinical Nutrition, 76, 460 465.
51. Melkersson, K. Dahl, M 2004). Adverse metabolic effects associated with atypical antipsychotics. Drugs, 64, 701 723.
52. Monto, A., Alonzo, J., Watson, J. J., Grunfeld, C. Wright, T. L 2002). Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology, 36, 729 736.
53. Murata, H., Hruz, P. W. Mueckler, M 2000). The mechanism of insulin resistance caused by HIV protease inhibitor therapy. Journal of Biological Chemistry, 275, 20251 20254.
54. Mynarcik, D. C., Combs, T., McNurlan, M. A., Scherer, P. E., Komaroff, E. Gelato, M. C 2002). Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. Journal of Acquired Immune Deficiency Syndrome, 31, 514 520.
55. Nolan, D 2003). Metabolic complications associated with HIV protease inhibitor therapy. Drugs, 63, 2556 2574.
56. Sande, M. A., Eliopoulos, G. M. Moellering, R. C 2005). The Sanford guide to HIV/AIDS therapy (14th ed New Hyde, VT : Antimicrobial Therapy.
57. Schambelan, M., Benson, C. A., Carr, A., Currier, J. S., Dube, M. P., Gerber, J. G, et al 2002). Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society - USA Panel. Journal of Acquired Immune Deficiency Syndrome, 31, 257 275.
58. Sherer, R 2003). HIV, HAART, and hyperlipidemia: Balancing the effects. Journal of Acquired Immune Deficiency Syndrome, 34 (Suppl. 2 S123 S129.
59. Shintani, Y., Fujie, H., Miyoshi, H., Tsutsumi, T., Tsukamoto, K., Kimura, S, et al 2004). Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology, 126, 840 848.
60. Sutinen, J., Hakinnen, A., Westerbacka, J., Seppala-Lindroos, A., Vehkavaara, S., Halavaara, J, et al 2002). Increased fat accumulation in the liver of HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS, 16, 2183 2193.
61. Tanwani, L. K. Mokshagundam, S. L 2003). Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection. Southern Medical Journal, 96, 180 188.
62. Tershakovec, A. M., Frank, I. Rader, D 2004). HIV-related lipodystrophy and related factors. Atherosclerosis, 174, 1 10.
63. White, J. R., Campbell, R. K 2003). Insulin in the treatment of type 2 diabetes mellitus. American Journal of Health-System Pharmacy, 60 (11 1145 1152.
64. Woerle, H. J., Mariuz, P. R., Meyer, C., Reichman, R. C., Popa, E. M., Dostou, J. M, et al 2003). Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes, 52, 918 925.
65. Wyne, K. L., Drexler, A. J., Miller, J. L., Bell, D. S. H., Braunstein, S. Nuckolls, J. G 2003). Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones [Special report]. Postgraduate Medicine, May, Spec No, 63 72.
66. Yarasheski, K. E., Tebas, P., Stanerson, B., Claxton, S., Marin, D., Bae, K, et al 2001). Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with anti-retroviral therapy. Journal of Applied Physiology, 90, 133 138.
67. Yeni, P. G., Hammer, S. M., Carpenter, C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M, et al 2002). Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society - USA Panel. Journal of the American Medical Association, 288, 222 235.
68. Yu, Y. H. Ginsberg, H. N 2005). Adipocyte signaling and lipid homeostasis sequalae of insulin-resistant adipose tissue. Circulation Research, 96, 1042 1052.